Taha Merghoub
#163,548
Most Influential Person Now
Researcher
Taha Merghoub's AcademicInfluence.com Rankings
Taha Merghoubengineering Degrees
Engineering
#7145
World Rank
#8508
Historical Rank
Biomedical Engineering
#692
World Rank
#704
Historical Rank
Electrical Engineering
#2204
World Rank
#2310
Historical Rank
Applied Physics
#2411
World Rank
#2452
Historical Rank
Download Badge
Engineering
Taha Merghoub's Degrees
- PhD Biomedical Engineering University of California, Berkeley
- Masters Electrical Engineering Stanford University
Why Is Taha Merghoub Influential?
(Suggest an Edit or Addition)Taha Merghoub's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (2015) (5602)
- Genetic basis for clinical response to CTLA-4 blockade in melanoma. (2014) (3103)
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
- Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer (2018) (1203)
- Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018) (908)
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2015) (750)
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010) (748)
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer (2017) (720)
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer (2018) (688)
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy (2014) (598)
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells (2016) (581)
- Chromatin states define tumor-specific T cell dysfunction and reprogramming (2017) (547)
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2016) (516)
- Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. (2012) (462)
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy (2017) (445)
- Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer (2016) (426)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) (423)
- Role of the proto-oncogene Pokemon in cellular transformation and ARF repression (2005) (345)
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. (2018) (342)
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. (2015) (342)
- Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient (2017) (341)
- Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. (2011) (319)
- Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. (2014) (247)
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation (2010) (240)
- CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors (2019) (230)
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis (2017) (225)
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis (2009) (217)
- Progression of RAS-mutant leukemia during RAF inhibitor treatment. (2012) (216)
- Regulation of B Versus T Lymphoid Lineage Fate Decision by the Proto-Oncogene LRF (2007) (212)
- Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. (2006) (209)
- Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. (2018) (194)
- Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (2020) (194)
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF (2012) (192)
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity (2020) (187)
- Alternative transcription initiation leads to expression of a novel ALK isoform in cancer (2015) (186)
- BCL-6 regulates chemokine gene transcription in macrophages (2000) (186)
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (2019) (181)
- Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. (2002) (169)
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition (2020) (151)
- Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation (2014) (151)
- Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways (2021) (151)
- Rational design of anti-GITR-based combination immunotherapy (2019) (144)
- Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. (2021) (142)
- Maternally transmitted severe glucose 6‐phosphate dehydrogenase deficiency is an embryonic lethal (2002) (140)
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (2021) (138)
- Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway (2014) (137)
- Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype (2012) (136)
- Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine (2020) (134)
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability (2013) (133)
- CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors (2021) (126)
- In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide (2016) (123)
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells (2016) (116)
- In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications (1999) (113)
- Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. (2015) (112)
- Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors (2016) (111)
- Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. (2017) (109)
- Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. (2018) (108)
- Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. (2010) (108)
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2017) (106)
- LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. (2009) (105)
- Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response (2009) (104)
- Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade (2017) (104)
- Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity (2017) (102)
- Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade (2018) (97)
- Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy (2018) (96)
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy (2018) (95)
- Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade (2016) (95)
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade (2018) (94)
- Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. (2006) (92)
- Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells (2017) (91)
- Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment (2017) (90)
- Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor (2013) (89)
- Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1 (2001) (82)
- Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. (2014) (76)
- The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. (2010) (75)
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer (2020) (71)
- Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. (2004) (70)
- Pharmacologic modulation of RNA splicing enhances anti-tumor immunity (2021) (70)
- An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity (2017) (68)
- Metastasis and immune evasion from extracellular cGAMP hydrolysis. (2020) (67)
- Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer (2019) (66)
- The importance of animal models in tumor immunity and immunotherapy. (2014) (65)
- Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity (2010) (61)
- Disruption of PLZP in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis (2004) (57)
- Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. (2021) (55)
- Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors (2017) (55)
- Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies (2016) (53)
- Escape from nonsense-mediated decay associates with anti-tumor immunogenicity (2019) (51)
- Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC (2020) (51)
- A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. (2015) (50)
- T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks (2014) (49)
- Neutrophil phenotypes and functions in cancer: A consensus statement (2022) (47)
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. (2018) (47)
- Erratum: Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (Cell (2015) 162(5) (974–986) (S009286741500848X) (10.1016/j.cell.2015.07.011)) (2017) (46)
- Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy (2016) (45)
- Vaccinia Virus Subverts a Mitochondrial Antiviral Signaling Protein-Dependent Innate Immune Response in Keratinocytes through Its Double-Stranded RNA Binding Protein, E3 (2008) (45)
- An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. (2019) (45)
- The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. (2015) (42)
- Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway (2011) (39)
- Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. (2016) (37)
- Using LIBS to diagnose melanoma in biomedical fluids deposited on solid substrates: Limits of direct spectral analysis and capability of machine learning (2018) (37)
- Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. (2017) (36)
- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer (2019) (35)
- EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors (2012) (34)
- Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. (2008) (33)
- Combination of Alphavirus Replicon Particle–Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates (2014) (32)
- Spectrum of β‐Thalassemia Mutations in Oman a (1998) (32)
- Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect (2019) (31)
- PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. (2017) (31)
- Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain (2012) (31)
- In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. (2019) (30)
- New method for quantitative determination of fetal hemoglobin-containing red blood cells by flow cytometry: application to sickle-cell disease. (1998) (28)
- LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade (2021) (28)
- Neoantigen quality predicts immunoediting in survivors of pancreatic cancer (2022) (27)
- Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer (2021) (26)
- Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. (2014) (25)
- First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. (2016) (25)
- Anatomic position determines oncogenic specificity in melanoma (2020) (25)
- Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus (2018) (24)
- Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. (2017) (23)
- OX 40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis (2009) (23)
- Antiangiogenic therapy and immune checkpoint blockade go hand in hand. (2017) (23)
- HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers (2017) (23)
- Strategies for Predicting Response to Checkpoint Inhibitors (2018) (23)
- Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. (2020) (22)
- 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One (2017) (22)
- Variation of fetal hemoglobin and F-cell number with the LCR-HS2 polymorphism in nonanemic individuals. (1996) (21)
- Mechanisms of immunization against cancer using chimeric antigens. (2008) (19)
- IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients (2016) (19)
- Molecular Basis of β‐Thalassemia in Bahrain: An Epicenter for a Middle East Specific Mutation a (1998) (18)
- iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy (2020) (18)
- Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope (2011) (18)
- Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma (2022) (18)
- Dissection of the association status of two polymorphisms in the β‐globin gene cluster with variations in F‐cell number in non‐anemic individuals (1997) (18)
- Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias. (2001) (18)
- The neoantigen landscape underlying clinical response to ipilimumab. (2014) (17)
- Immune rejection of mouse tumors expressing mutated self. (2009) (17)
- Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial (2020) (17)
- A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC). (2018) (17)
- The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein (2016) (17)
- Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. (2016) (15)
- Spectrum of beta-thalassemia mutations in Oman. (1998) (15)
- Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer (2021) (15)
- Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody (2018) (15)
- NSCLC, early stageNeoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer (2016) (14)
- A novel C→A transversion within the distal CCAAT motif of the Gγ-globin gene in the algerian Gγβ+-hereditary persistence of fetal hemoglobin (1999) (14)
- Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM) (2017) (14)
- Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer (2020) (14)
- Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. (2018) (13)
- Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. (2011) (13)
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. (2018) (13)
- Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma (2019) (12)
- Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent (2013) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer (2019) (11)
- The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. (2018) (11)
- Massively parallel sequencing analysis of benign melanocytic naevi (2019) (10)
- Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepatocellular carcinoma (HCC). (2020) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Haemoglobin D-Ouled Rabah among the Mozabites: A Relevant Variant to Trace the Origin of Berber-Speaking Populations (1997) (10)
- Polyphenols from Pennisetum glaucum grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells (2019) (9)
- The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease (2008) (9)
- The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade. (2012) (9)
- mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. (2017) (9)
- mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition (2017) (8)
- Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation (2017) (8)
- Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (2019) (8)
- Genetics and immunology: reinvigorated (2015) (8)
- Microenvironment and Immunology Monocytic CCR 2 þ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD 8 T-cell In fi ltration into the Tumor Microenvironment (2012) (8)
- Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC). (2019) (7)
- Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets). (2013) (7)
- A novel C-->A transversion within the distal CCAAT motif of the Ggamma-globin gene in the Algerian Ggammabeta+-hereditary persistence of fetal hemoglobin. (1999) (7)
- Abstract 4716: Targeting specific TGF-β isoforms in combination with radiation therapy leads to differential antitumor effects in mouse models of cancer (2018) (7)
- Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases (2022) (7)
- Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial (2017) (7)
- Molecular basis of beta-thalassemia in Bahrain: an epicenter for a Middle East specific mutation. (1998) (7)
- Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (7)
- Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma (2022) (6)
- A delicate interplay between adaptive and innate immunity caused by immunotherapy triggers tumor immunity and aseptic inflammation (2018) (6)
- Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia (2021) (6)
- Myeloid-derived suppressor cells and the efficacy of CD8+ T-cell immunotherapy (2013) (6)
- Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR (DigPCR) with tumor burden measured radiographically in patients (pts) with BRAFV600E mutated melanoma (mel) treated with RAF inhibitor (RAFi) and/or ipilimumab (Ipi). (2014) (6)
- Development of effective vaccines for old mice in a tumor model. (2009) (6)
- In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology (2021) (5)
- One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade. (2019) (5)
- CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors (2020) (5)
- Abstract B109: In-depth tissue analysis using multiplexed immunohistochemical consecutive staining on single slide (2016) (5)
- Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia: a case report and review of the literature. (2002) (5)
- Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway (2011) (5)
- Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer (2019) (5)
- Regional and clonal T cell dynamics at single cell resolution in immune checkpoint blockade (2021) (5)
- In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response (2022) (4)
- Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells (2016) (4)
- Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models (2019) (4)
- Curbing Tregs’ (Lack of) Enthusiasm (2017) (4)
- Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR (2016) (4)
- Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2 (2016) (4)
- Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma (2017) (4)
- Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors (2022) (4)
- Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. (2015) (3)
- Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness. (2020) (3)
- Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment (2016) (3)
- Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization (2017) (3)
- Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer (2018) (3)
- Abstract 554: Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models (2016) (3)
- Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets (2020) (3)
- Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions (2022) (3)
- The cytosolic DNA- and RNA-sensing pathways play important and non-redundant roles in host defense against vaccinia infection (2017) (3)
- Abstract 1651: Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model (2017) (2)
- Multi-omic analysis of urothelial cancer patients treated with PD-L1 blockade demonstrates the contribution of both systemic and somatic factors to the biology of response and resistance (2016) (2)
- Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine (2022) (2)
- Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer (2021) (2)
- Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness (2021) (2)
- Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. (2020) (2)
- Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors (2014) (2)
- Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism (2022) (2)
- Abstract 4723: Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor (2018) (2)
- A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation (2020) (2)
- Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses (2020) (2)
- Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer. (2021) (2)
- Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer (2021) (2)
- Abstract PR06: Overcoming intratumor T-cell exclusion by modulation of lactate metabolism to improve immune checkpoint therapies in aggressive breast cancer (2016) (2)
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity (2020) (2)
- Spectrum of β-Thalassaemia Mutations in Bahrain ♣ (2000) (2)
- Hemoglobin sickle-lepore: an unusual case of sickle cell disease. (1997) (2)
- P2.04-24 Transcriptional Profiling of Neoantigen Specific T Cells in Resectable NSCLC Treated with Neoadjuvant Anti-PD-1 (2019) (2)
- Chapter 36 – Molecular Biology of Melanoma (2008) (2)
- Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC). (2022) (2)
- T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants (2023) (2)
- Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. (2014) (1)
- Immunotherapy and the belly of the beast (2014) (1)
- POKEMON Is a Proto-Oncogene Which Plays a Key Role in Lymphomagenesis. (2004) (1)
- Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients (2019) (1)
- MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade (2018) (1)
- Abstract 4742: Anti-tyrosinase related protein 1 (TRP1) antibody combined with cyclophosphamide induces adaptive immunity against melanoma (2011) (1)
- Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection (2013) (1)
- Abstract 250: Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy (2022) (1)
- Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells (2017) (1)
- Immuno-PET imaging of activation markers on antigen-specific CD4 T cells in a mouse model of melanoma (2019) (1)
- Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53 (2022) (1)
- Author response: T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks (2014) (1)
- Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab. (2015) (1)
- Intratumoral delivery of engineered recombinant modified vaccinia virus Ankara expressing Flt3L and OX40L generates potent antitumor immunity through activating the cGAS/STING pathway and depleting tumor-infiltrating regulatory T cells (2021) (1)
- Abstract B09: Heterogeneous fates of metastatic lesions linked to immune escape in an ovarian cancer patient (2017) (1)
- The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. (2022) (1)
- HLA CLASS II GENOTYPES AND COW MILK PROTEIN ALLERGY (CMPA) IN 47 INFANTS. (1997) (1)
- Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (1)
- Blockade of IDO/TDO downstream effectors restricts cancer immune suppression (2019) (1)
- Abstract 1699: Treatment with agonist anti-GITR antibody after chemotherapy enhances tumor immunity (2018) (1)
- 493 Tired and hungry: a potential role for CD47 in T cell exhaustion (2020) (1)
- Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. (2023) (1)
- Mutations of the PML tumor suppressor gene in APL (2003) (1)
- A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). (2019) (1)
- Abstract 2711: Rational combination of GITR agonism with PD-1 blockade (2019) (1)
- T Cell Immunotherapies Trigger Neutrophil Activation to Eliminate Tumor Antigen Escape Variants (2020) (1)
- Abstract 3257: CTLA-4 blockade drives loss of regulatory T cell functional stability in glycolysis defective tumors (2020) (1)
- Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models. (2018) (1)
- Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients. (2022) (1)
- Abstract LB-306: Oncolytic vaccinia virus expressing immune checkpoint blockade antibody as cancer immunotherapeutics (2018) (1)
- Interaction between Kynurenine and the AhR is an effector mechanism of tumor immunosuppression and represents a potential immunotherapy target (2018) (1)
- Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms (2020) (1)
- Correction to: Strategies for Predicting Response to Checkpoint Inhibitors (2018) (1)
- In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. (2020) (1)
- Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC). (2020) (1)
- Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (2021) (1)
- Blockade of surface bound TGF-β on regulatory T cells abrogates suppression of effector T cell function within the tumor microenvironment (TUM2P.1015) (2015) (1)
- Abstract B26: Immune-active microenvironment in SCCOHT: Rationale for therapy with immune checkpoint blockade (2018) (0)
- Abstract 5217: Defining the balance of anti-viral and anti-tumor T cell responses to oncolytic virus therapy using single cell approaches (2022) (0)
- Neoantigen homology and predicting response to immune checkpoint blockade in cancer (2015) (0)
- Agonist anti-GITR antibody synergizes with cyclophosphamide (CTX) to induce tumor immunity (2008) (0)
- Investigation of the immunological mechanisms underlying the attenuation of vaccinia virus lacking host-range factor C7 (2018) (0)
- Heat-inactivated modified vaccinia virus Ankara boosts Th1-biased cellular and humoral immune responses as a vaccine adjuvant by activating the STING-mediated cytosolic DNA-sensing pathway (2021) (0)
- Upper tract urothelial carcinoma transcriptome profiling and immune microenvironment characterization. (2022) (0)
- 834 Rational design of recombinant modified vaccinia virus Ankara for cancer immunotherapy (2019) (0)
- OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. (2023) (0)
- Abstract 6150: Potential role of CD47 in T cell exhaustion program (2022) (0)
- Abstract PR05: Blockade of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression (2020) (0)
- 696 Single-cell RNA-seq reveals the critical roles of the STING- and MDA5-mediated cytosolic nucleic acid-sensing pathways as well as IFNAR/STAT2 signaling in recombinant MVA-induced antitumor immunity (2021) (0)
- CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response (40.33) (2009) (0)
- CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer (2022) (0)
- Abstract B183: Treg inhibition by anti-GITR therapy evokes therapeutic antitumor responses selectively in the context of a pro-inflammatory tumor microenvironment (2016) (0)
- 218 Immunogenic landscape and therapeutic targeting of mutantNRAS”public” neoantigens (2022) (0)
- Leveraging CD39 To Identify Tumor-Reactive CD8 T cells In Human Lung Cancer (2022) (0)
- Abstract IA34: Mapping immune recognition of non-self neoantigens in human pancreatic cancer (2019) (0)
- Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies (2016) (0)
- 549 Characterizing double positive T cells in the tumor microenvironment: a tale of promiscuous cell fates (2020) (0)
- Abstract 5666: A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer (2020) (0)
- Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model (2017) (0)
- Issue Information (2019) (0)
- Abstract 4167: Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model (2022) (0)
- Abstract A125: Pulsatile MEK inhibition improves antitumor immunity and T-cell function in Kras mutant lung cancer (2019) (0)
- Abstract 2160: MCT4 blockade reverses lactate-mediated immunosuppression in LKB1-deficient NSCLC (2022) (0)
- Abstract 2517: Optimizing breast cancer therapy by inhibiting the adenosine receptor and oxygen consumption (2023) (0)
- Conditional Inactivation of the Proto-Oncogene Pokemon Results in Block of Differentiation in Multiple Hematopoietic Lineages. (2005) (0)
- Efferent immune-mechanical activities reflect cell function and state. (2023) (0)
- 020 The combination of intratumoral delivery of inactivated modified vaccinia virus Ankara with systemic delivery of immune checkpoint blockade enhances antitumor immunity (2018) (0)
- OP-JNCI170353 787..790 (2018) (0)
- Paving the Way for Cancer Therapy a Nano Step at a Time (2023) (0)
- Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment (2014) (0)
- Abstract 5009: Defined factors overcome T-cell exhaustion via abscopal effect (2018) (0)
- Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer (2021) (0)
- Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (0)
- Fundamental immune–oncogenicity trade-offs define driver mutation fitness (2022) (0)
- 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination (2020) (0)
- MP69-20 CHARACTERIZING THE IMMUNE PHENOTYPE OF FGFR3 MUTATED UPPER TRACT UROTHELIAL CARCINOMA (UTUC) USING SINGLE-CELL (SC)RNA-SEQUENCING (SEQ) (2023) (0)
- 697 Rational engineering of recombinant modified vaccinia virus Ankara to enhance both innate and adaptive immunity for cancer immunotherapy (2021) (0)
- Abstract 1795: Combination of cyclophosphamide chemotherapy with immune modulation overcomes resistance to checkpoint blockade in a pre-clinical melanoma model (2021) (0)
- Abstract 2402: GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human (2019) (0)
- Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in mice via multichannel image segmentation. (2022) (0)
- Rational design of anti-GITR-based combination immunotherapy (2019) (0)
- Abstract 3537: Pharmacologic inhibition of the glycolytic pathway improves response to immune checkpoint blockade (2022) (0)
- Agonist anti-GITR antibody induces CD8 T cell-mediated tumor rejection (2007) (0)
- Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade (2022) (0)
- MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade (2019) (0)
- 1283 In vivo phenotyping of the tumor immune microenvironment to predict melanoma outcomes (2023) (0)
- Abstract IA04: Overcoming immune resistance with rationally designed combination immunotherapy (2020) (0)
- TRAIL/DR5 Interactions Are Important For Mediating Thymic Damage After Allogeneic Bone Marrow Transplantation (2010) (0)
- Expression of indoleamine 2.3-dioxygenase (IDO) by tumors induces local and systemic immunosuppressive effects in a murine melanoma model (TUM10P.1029) (2015) (0)
- Immunologic Study of Tumors in Mouse Models (2004) (0)
- Neoantigen quality predicts immunoediting in survivors of pancreatic cancer (2022) (0)
- A novel polymorphism 3' to the beta-globin gene. (1998) (0)
- Abstract 5873: LDH inhibition boosts effector T cells while destabilizing regulatory T cells and improves responses to CTLA-4 blockade (2023) (0)
- Pokemon represses art in promoting cellular transformation (2005) (0)
- Abstract PR09: Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for "in situ" therapeutic cancer vaccination (2019) (0)
- Clonal evolution of uveal melanoma metastases. (2018) (0)
- Abstract 2421: WST-11 vascular-targeted photodynamic therapy induced immune modulation in upper tract urothelial cancer (2023) (0)
- Abstract 923: Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer (2020) (0)
- Abstract 2767: Phosphatidylserine targeting and radiation improves survival in a mouse tumor model resistant to checkpoint blockade (2018) (0)
- 625 Loss of soluble adenylyl cyclase is a marker of invasive melanoma and facilitates melanomagenesis (2016) (0)
- Abstract C138: Loss of NF1 in melanoma cell lines is associated with active Ras and dependence on MEK even in the absence of BRAF or NRAS mutation. (2013) (0)
- 1148 Signal-regulatory protein alpha (SIRPα) confers tumor cell resistance to anti-tumor immunity (2022) (0)
- The T Cell Cytolytic Molecules Fas Ligand And Trail, The Trafficking Molecules CCR9, β7 Integrin And PSGL1, And The Immune Modulating Molecules OX40 And Ceacam1 Are Required For Thymic Graft-Versus-Host Disease (2009) (0)
- Alphavirus replicon particles expressing melanocyte differentiation antigens are effective vaccines for melanoma (41.55) (2009) (0)
- 35336 Effect of Nuclear Soluble Adenylyl Cyclase (sAC) on Melanoma Treatment Response (2021) (0)
- Abstract LB135: Deferiprone alters macrophage function and metabolism (2022) (0)
- Tumor-Expressed IDO Rec ruits and Activates MDSCs in a Treg-Dependent Manner Graphical Abstract Highlights (2015) (0)
- Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment (2014) (0)
- Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA) (2020) (0)
- A New Mechanism Of Immune Regulation That Limits The Efficacy Of Immunotherapy (2018) (0)
- 567 Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers (2021) (0)
- TRAIL/ DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation. (2009) (0)
- leukemia Mutations of the PML tumor suppressor gene in acute promyelocytic (2013) (0)
- 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination (2021) (0)
- Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma (2011) (0)
- Abstract B031: Heat-inactivated modified vaccinia virus ankara induces type I IFN and antitumor immunity via the cytosolic DNA-sensing pathway (2016) (0)
- Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant (2022) (0)
- Abstract A007: Intratumoral delivery of inactivated vaccinia virus is more efficacious than live oncolytic vaccinia virus in murine bilateral tumor implantation models (2016) (0)
- 619 Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy (2021) (0)
- 604 Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response (2020) (0)
- CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response (2009) (0)
- 643 Immunoprevention of dysplastic nevi in mice polarity promotes melanoma metastasis by regulating canonical Wnt signaling and EMT pathways Melanoma and the protective role of phosphorylated a -syn (pSer129) to prevent malignant degeneration (0)
- OX40 engagement promotes potent tumoricidial CD4+ T cells (P2199) (2013) (0)
- Evaluation of the Immunologic Impact of RAF Inhibitors to Guide Optimal Combination of RAF Inhibitors and Immunotherapy for the Treatment of Advanced Melanoma (2016) (0)
- 791 Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model (2022) (0)
- Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment (2013) (0)
- A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study) (2020) (0)
- Abstract 978: Tim-4+tissue-resident macrophages impair antitumor T-cell immunity (2019) (0)
- Abstract B059: Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to regress tumors systemically (2016) (0)
- Abstract 3568: Phosphatidylserine targeting antibody enhances antitumor activity of CAR T cells in mouse melanoma (2018) (0)
- 843 Lag3 blockade in combination with GITR improves anti-tumor immune responses in a preclinical melanoma model (2022) (0)
- Abstract 4427: Cucurbitacin B: A promising drug candidate for targeting tumor immunosuppressive cells (2023) (0)
- Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model (2014) (0)
- Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysis (2017) (0)
- Abstract IA10: Targeting melanoma metabolism to overcome resistance to treatment (2020) (0)
- Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. (2016) (0)
- 635 Reprogramming the tumor microenvironment by a second-generation recombinant modified vaccinia virus Ankara (2022) (0)
- TGF-β dependent suppression of effector T cell function within the tumor microenvironment (P2033) (2013) (0)
- Modulation of TFH-like cells and anti-tumor activity of immune checkpoint blockade. (2018) (0)
- Abstract 632: Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a non-small cell lung cancer patient (2017) (0)
- IL-12-expressing highly immunogenic recombinant modified vaccinia virus Ankara reprograms tumor-infiltrating myeloid cells to overcome immune resistance (2022) (0)
- 99 T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants (2021) (0)
- LRF/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling. (2006) (0)
- Abstract #5657: Agonist anti-GITR monoclonal antibody targets both regulatory and effector T cells to induce tumor immunity (2009) (0)
- An Immune Cell Recirculation-Enabled Microfluidic Array to Study Dynamic Immunotherapeutic Activity in Recapitulated Tumor Microenvironment (2022) (0)
- Abstract 610: Modeling tumor immunoediting coupled with T-cell repertoire dynamic (2023) (0)
- 904 LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression (2022) (0)
- 347 Development of optimized CAR T cells for therapy of glioblastoma (2022) (0)
- Amendment history : Corrigendum ( October 2018 ) PD-L 1 in tumor microenvironment mediates resistance to oncolytic immunotherapy (2018) (0)
- 524 Tim-4+ resident macrophages impair anti-tumor immunity in the serous body cavities By sequestering viable and cytotoxic CD8+ T cells expressing high levels of phosphatidylserine (2020) (0)
- Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer (2022) (0)
- 903 APR-246 induces an increase in tumor immunogenicity in a p53 independent manner (2022) (0)
- Abstract LB-081: A nuclear cAMP microdomain functions as a tumor suppressor in melanoma (2019) (0)
- 327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma (2021) (0)
- Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy (2015) (0)
- Abstract 874: Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy (2017) (0)
- Gene Knockouts in Cancer Research (2007) (0)
- MCT4-Dependent Lactate Secretion Suppresses Antitumor Immunity in LKB1-Deficient NSCLC (2022) (0)
- A role for the GITR pathway in anaphylaxis (P4326) (2013) (0)
- 997 T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors (2022) (0)
- Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases (2022) (0)
- Abstract 3735: An anti-tumor immune response is evoked by partial-volume single dose radiation (2019) (0)
- Abstract 4175: Combining a novel MEK inhibitor with immunomodulation to promote an anti-tumor response (2022) (0)
- Inhibition of Treg suppression by GITR stimulation causes tumor regression selectively in the context of a pro-inflammatory tumor microenvironment (TUM9P.1005) (2015) (0)
- Abstract 2: Vertical MAPK pathway targeting in novel genetically engineered mouse and cell line models of NF1-altered melanoma: the mSK-Mel murine cohort (2023) (0)
- Immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type provides a rationale for evaluating immunotherapies to treat this malignancy (2018) (0)
- Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody. (2007) (0)
- MP48-02 SINGLE CELL RNA SEQUENCING OF UTUC IS FEASIBLE AND REVEALS HETEROGENEITY OF THE TUMOR AND IMMUNE MICROENVIRONMENT (2021) (0)
- Effect of self antigen specific CD4+ T cell precursor frequency on the anti-tumor immune response: Implications for adoptive T cell therapy (P2040) (2013) (0)
- 034 Recombinant replication competent attenuated vaccinia virus expressing human Flt3L for cancer immunotherapy (2016) (0)
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (2019) (0)
- Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC (2019) (0)
- Abstract B02: Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy (2019) (0)
- Abstract 5742: Pharmacologic modulation of RNA splicing enhances anti-tumor immunity (2023) (0)
- 254 CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors (2020) (0)
- 834 In vivo phenotyping of the tumor-immune microenvironment in skin cancers (2022) (0)
- Abstract 1476: Vessel normalization following LDH-A knockdown in murine breast tumors (2020) (0)
- Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer (2019) (0)
- Phosphatidylserine targeting antibody enhances anti-tumor activity of adoptive cell therapies in a mouse melanoma model (2020) (0)
- Abstract PR09: Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Taha Merghoub?
Taha Merghoub is affiliated with the following schools:
